Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
|Articles|July 28, 2022
Daily OTC Pearl: EmuaidMax
Author(s)Saro Arakelians, PharmD
Topical symptomatic relief for resistant skin conditions, including severe boils, hemorrhoids, eczema, cold sores, fungal infections, psoriasis, poison ivy, oak and sumac, and other itchy, painful conditions.
Advertisement
OTC/Lifestyle Pearl of the Day: EmuaidMax
Indication: Topical symptomatic relief for resistant skin conditions, including severe boils, hemorrhoids, eczema, cold sores, fungal infections, psoriasis, poison ivy, oak and sumac, and other itchy, painful conditions.
Insight:
- Thoroughly clean the affected area.
- Apply a thin layer of EmuaidMax.
- Reapply 3-4 times daily or as needed for additional symptomatic relief.
- Keep away from children.
- Store at room temperature.
Source:
Advertisement
Related to this article
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.
The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5